Is Lecanemab Plus t-PA A Deadly Combination? One Case Study May Shed Light
Anticoagulant Use In Spotlight As Approval Nears
A letter in the New England Journal of Medicine suggests the death of one extension trial participant treated with t-PA may have been caused by lecanemab, but a response notes fatal intracerebral hemorrhages have been seen after t-PA in certain patients in the absence of anti-amyloid drugs.
